Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New Havas company focused on fostering scientific understanding of cannabinoids

The Havas Health & You network introduced Havas ECS, a specialized strategic communications advisory and education company focused on the importance and value of foundational scientific knowledge on the endocannabinoid system

Read More »

Opiant Expands Partnership with Sanofi

Opiant Pharmaceuticals Inc. announced an agreement with Sanofi to manufacture Opiant’s investigational agent OPNTOO4 (drinabant) for the treatment of Acute Cannabinoid Overdose.

Read More »

Havas Health & You Launches Havas ECS

Havas Health & You introduced Havas ECS, a specialized strategic communications advisory and education company focused on the importance and value of foundational scientific knowledge on the endocannabinoid system,

Read More »

PPM Releases White Paper about Cannamimetics Science and Applications

Precision Plant Molecules (PPM) coined the term Cannamimetics to describe naturally inspired ways to access important, bioactive “minor” cannabinoids that currently manifest in existing hemp cultivars in de minimis concentrations. More effective plant-based extracts and concentrates can be formulated with these cannabinoids.

Read More »

Insys Therapeutics Files for Bankruptcy

Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.

Read More »

Opiant’s Mid-Stage Treatment for a Severe Eating Disorder Fails to Reach Endpoints

Shares of Opiant Pharmaceuticals fell in trading after the company announced that the Phase II trial evaluating a naloxone nasal spray for the treatment of bulimia nervosa failed to meet primary endpoints and will discontinue the program.

Read More »

Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi

Opiant Pharmaceuticals Inc., a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced an exclusive global licensing agreement with Sanofi for the development and commercialization of drinabant for the treatment of acute cannabinoid overdose (ACO).

Read More »

Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate

There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.

Read More »

INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation

INSYS Therapeutics Inc. announced today that the company reached an agreement in principle with the Department of Justice to settle the DOJ’s civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.

Read More »

DEA Moving Forward With Reclassification of CBD Ahead of GW’s Launch of Epidiolex

The U.S. Drug Enforcement Agency is readdressing cannabis following the regulatory approval of the first cannabinoid-based drug for the treatment of some epilepsy patients.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom